Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Joel Sendek as Chief Financial Officer, effective September 4, 2025. Sendek brings significant experience as a biotech CFO and Wall Street analyst, having previously served as CFO at Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma.
As CFO, Sendek has successfully raised over $2.5 billion in corporate transactions. His background includes leadership roles at Stifel, Lazard, and Oppenheimer, where he earned Wall Street Journal recognition as an All-Star Analyst with a #1 ranking in stock picking. He succeeds Juan Graham in the role.
Perspective Therapeutics (NYSE AMERICAN: CATX), azienda di radiofarmaci, ha nominato Joel Sendek Chief Financial Officer, con decorrenza dal 4 settembre 2025. Sendek vanta una solida esperienza come CFO nel settore biotech e come analista di Wall Street; in passato ha ricoperto il ruolo di CFO presso Dewpoint Therapeutics, Sema4, Spero Therapeutics e Forward Pharma.
Nel corso della sua carriera da CFO ha raccolto con successo oltre 2,5 miliardi di dollari tramite operazioni societarie. Ha inoltre ricoperto posizioni di leadership presso Stifel, Lazard e Oppenheimer, ottenendo il riconoscimento del Wall Street Journal come All-Star Analyst con il primo posto nel picking azionario. Sostituisce Juan Graham nel ruolo.
Perspective Therapeutics (NYSE AMERICAN: CATX), una compañía de radiofármacos, ha nombrado a Joel Sendek como Director Financiero (CFO), con efecto a partir del 4 de septiembre de 2025. Sendek aporta amplia experiencia como CFO en biotecnología y como analista de Wall Street; anteriormente fue CFO en Dewpoint Therapeutics, Sema4, Spero Therapeutics y Forward Pharma.
Como CFO, Sendek ha logrado recaudar con éxito más de 2.500 millones de dólares en transacciones corporativas. Su trayectoria incluye cargos directivos en Stifel, Lazard y Oppenheimer, donde fue reconocido por el Wall Street Journal como All-Star Analyst, ocupando el puesto número uno en selección de acciones. Releva a Juan Graham en el cargo.
Perspective Therapeutics (NYSE AMERICAN: CATX)는 방사성의약품 기업으로서 Joel Sendek를 최고재무책임자(CFO)로 임명했으며, 임명일은 2025년 9월 4일입니다. Sendek는 바이오텍 CFO와 월스트리트 애널리스트로서 풍부한 경험을 보유하고 있으며, 이전에 Dewpoint Therapeutics, Sema4, Spero Therapeutics 및 Forward Pharma에서 CFO를 역임했습니다.
CFO로서 Sendek는 기업 거래를 통해 25억 달러 이상을 성공적으로 조달했습니다. 또한 Stifel, Lazard, Oppenheimer에서의 리더십 경력이 있으며, 주식 선정 부문에서 1위를 기록한 All-Star Analyst로 월스트리트저널의 인정을 받았습니다. 그는 Juan Graham의 후임입니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une société de radiopharmaceutiques, a nommé Joel Sendek Chief Financial Officer, à compter du 4 septembre 2025. Sendek apporte une solide expérience en tant que CFO dans le secteur biotech et comme analyste de Wall Street; il a précédemment occupé le poste de CFO chez Dewpoint Therapeutics, Sema4, Spero Therapeutics et Forward Pharma.
En tant que CFO, Sendek a réussi à lever plus de 2,5 milliards de dollars au travers d'opérations corporatives. Il a également occupé des fonctions de direction chez Stifel, Lazard et Oppenheimer, où le Wall Street Journal l'a reconnu comme All-Star Analyst, classé n°1 en sélection d'actions. Il succède à Juan Graham.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein Radiopharma-Unternehmen, hat Joel Sendek zum Chief Financial Officer ernannt, wirksam ab dem 4. September 2025. Sendek bringt umfassende Erfahrung als CFO in der Biotech-Branche und als Wall-Street-Analyst mit und war zuvor CFO bei Dewpoint Therapeutics, Sema4, Spero Therapeutics und Forward Pharma.
In seiner Rolle als CFO hat Sendek erfolgreich über 2,5 Milliarden US-Dollar durch Unternehmensgeschäfte eingeworben. Zu seinen Stationen zählen Führungspositionen bei Stifel, Lazard und Oppenheimer; das Wall Street Journal zeichnete ihn als All-Star Analyst mit Platz 1 im Stock Picking aus. Er folgt auf Juan Graham.
- Appointment of experienced CFO with track record of raising over $2.5B in biotech sector
- New CFO brings Wall Street expertise and #1 ranked analyst credentials
- Strategic timing with three ongoing clinical programs
- CFO transition period may cause temporary operational adjustments
- Departure of previous CFO Juan Graham could impact continuity
Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investment landscape
SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company’s Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms.
Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed multiple transactions, raising over
“Joel’s financial leadership and expertise in biotech will be extremely valuable as we advance our clinical programs and work to establish the Company as a leader in the targeted alpha radiopharmaceutical field,” said Perspective’s CEO, Thijs Spoor. “His appointment comes at an exciting time for Perspective, with ongoing progress across all three of our clinical programs. I would like to welcome Joel to our senior team and look forward to his strategic insights and contributions.”
Mr. Sendek commented, “Perspective's technology has the potential to significantly expand the breadth of tumors that can be treated with radiopharmaceutical therapy. I’m joining because I view Perspective as the most attractive company within one of the most dynamic subsectors of the biotech industry today. My priority will be to support the advancement of this innovative platform and to help ensure the resources are in place to fully realize its potential.”
Mr. Sendek is succeeding Juan Graham, who will be leaving the Company. “I personally would like to thank Juan for his contributions and wish him well in his future endeavors,” added Mr. Spoor.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company’s ability to advance its clinical programs and establish the Company as a leader in the targeted alpha radiopharmaceutical field; the ability of the Company’s technology to significantly expand the breadth of tumors that can be treated with radiopharmaceutical therapy; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
Who is the new CFO of Perspective Therapeutics (CATX)?
What is Joel Sendek's track record in biotech financing?
What are Perspective Therapeutics' (CATX) current business priorities?
Who did Joel Sendek replace as CFO at Perspective Therapeutics (CATX)?
What recognition has Joel Sendek received in his career?
